PRX005

Migration, Crosslink

📖

PRX005

active

wiki page Created: 2026-04-02T07:20:05 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-entities-prx005

📖 Wiki Page

entity3656 wordssynced 2026-04-02

PRX005

Overview

PRX005 is a monoclonal antibody developed by Prothena in collaboration with Bristol Myers Squibb (BMS) targeting the microtubule-binding repeat (MTBR) region of tau protein for the treatment of Alzheimer's disease[@prothena2024]. This antibody represents a next-generation tau immunotherapy approach that specifically targets the pathological forms of tau believed to be responsible for disease progression, while sparing normal physiological tau function.

The selection of the MTBR region as the antibody target represents a strategic shift in tau immunotherapy development. Unlike earlier approaches that targeted the N-terminus or mid-domain regions of tau, PRX005 focuses on the region directly involved in tau-tau interactions and aggregate formation[@fitzpatrick2017]. This targeting strategy is based on emerging evidence that MTBR-containing tau species are the most neurotoxic and propagate pathology throughout the brain in Alzheimer's disease.

Background: Tau Biology and Alzheimer's Disease

Tau Protein Structure and Function

Tau is a microtubule-associated protein primarily expressed in neurons where it plays essential roles in maintaining cytoskeletal stability and axonal transport[@mandelkow2023]. The tau protein consists of several functional domains:

...

PRX005

Overview

PRX005 is a monoclonal antibody developed by Prothena in collaboration with Bristol Myers Squibb (BMS) targeting the microtubule-binding repeat (MTBR) region of tau protein for the treatment of Alzheimer's disease[@prothena2024]. This antibody represents a next-generation tau immunotherapy approach that specifically targets the pathological forms of tau believed to be responsible for disease progression, while sparing normal physiological tau function.

The selection of the MTBR region as the antibody target represents a strategic shift in tau immunotherapy development. Unlike earlier approaches that targeted the N-terminus or mid-domain regions of tau, PRX005 focuses on the region directly involved in tau-tau interactions and aggregate formation[@fitzpatrick2017]. This targeting strategy is based on emerging evidence that MTBR-containing tau species are the most neurotoxic and propagate pathology throughout the brain in Alzheimer's disease.

Background: Tau Biology and Alzheimer's Disease

Tau Protein Structure and Function

Tau is a microtubule-associated protein primarily expressed in neurons where it plays essential roles in maintaining cytoskeletal stability and axonal transport[@mandelkow2023]. The tau protein consists of several functional domains:

N-terminal projection domain: Projects away from microtubules and interacts with neuronal membranes

Proline-rich region: Contains multiple phosphorylation sites

Microtubule-binding repeat domain (MTBR): Consists of 3-4 repeat sequences (R1-R4) that directly bind to microtubules

C-terminal domain: Involved in tau aggregation regulation

The MTBR region contains highly conserved hexapeptide motifs (^306VQIVYK^311 and ^317VQIINK^322) that form the core of tau fibrils in Alzheimer's disease[@sawaya2023]. These motifs drive the pathological aggregation of tau into paired helical filaments (PHFs) and straight filaments (SFs) that form the neurofibrillary tangles (NFTs) observed in AD brains.

Tau Pathology in Alzheimer's Disease

The progression of tau pathology in AD follows a well-characterized pattern that correlates with clinical symptoms:

Braak stages I-II: Tau pathology limited to the transentorhinal cortex (early preclinical)

Braak stages III-IV: Involvement of limbic regions including hippocampus (MCI stage)

Braak stages V-VI: widespread cortical involvement (moderate to severe AD)

This hierarchical spread of tau pathology, known as "staging," reflects the prion-like propagation of pathological tau species between connected neurons[@jucker2023]. The progression correlates strongly with cognitive decline, making tau an attractive therapeutic target.

Limitations of Previous Tau Immunotherapies

Previous tau immunotherapy approaches have targeted various regions of the tau protein with limited success:

| Approach | Target | Limitations |
|----------|-------|-------------|
| N-terminal antibodies | Full-length tau | Binds normal tau, limited efficacy |
| Mid-domain antibodies | Phospho-epitopes | May not prevent aggregation |
| Conformational antibodies | Oligomers | Variable specificity |

The failures of first-generation tau antibodies, including gosuranemab and tilavonemab in Phase 3 trials, have informed the development of PRX005[@van2023]. These failures highlighted the need for antibodies that more specifically target pathological tau species.

Mechanism of Action

MTBR Region Targeting

PRX005 specifically binds to the MTBR region of tau, which contains the key aggregation-driving sequences[@shi2021]. This targeting strategy offers several advantages:

Selectivity for Pathological Tau:

The MTBR region is more exposed in pathological tau aggregates
Conformational changes in aggregated tau reveal MTBR epitopes
Normal tau has limited antibody accessibility to MTBR

Mechanism of Action:
PRX005 exerts its therapeutic effects through multiple mechanisms:

Aggregation blockade: Binding to MTBR prevents tau-tau interactions required for fibril formation

Seeding inhibition: Neutralizes extracellular tau seeds that propagate pathology

Clearance promotion: Fc-mediated microglial phagocytosis of bound tau species

Propagation blocking: Prevents cell-to-cell transmission of pathological tau

Preclinical Evidence

Studies in tau transgenic mouse models demonstrated that PRX005:

Reduces insoluble tau aggregates in brain tissue
Decreases tau phosphorylation at multiple epitopes
Improves performance on behavioral tests of cognition
Shows good brain penetration after peripheral administration
Does not displace normal tau from microtubules[@prothena2023]

Comparison with Other Tau-Targeting Approaches

| Antibody | Company | Target | Epitope | Specificity |
|----------|---------|--------|---------|-------------|
| PRX005 | Prothena/BMS | MTBR | R3-R4 | Pathological tau |
| Semorinemab | AC Immune/Roche | pT181 | Phospho-tau | All pT181 tau |
| Gosuranemab | Biogen | N-terminus | Residues 6-23 | All N-terminal tau |
| Tilavonemab | AbbVie | N-terminus | Residues 25-30 | All N-terminal tau |
| JNJ-63733657 | Janssen | Mid-domain | residues 224-369 | Phospho-tau |

The targeting of MTBR distinguishes PRX005 from all other tau antibodies in clinical development, representing a unique mechanism of action[@blennow2024].

Clinical Development

Phase 1 Study (NCT05509469)

PRX005 entered clinical development with a first-in-human Phase 1 study:

Study Design:

Randomized, double-blind, placebo-controlled
Single ascending dose (SAD): 0.5, 1.5, 5, 10, 20 mg/kg
Multiple ascending dose (MAD): 5, 10, 20 mg/kg monthly × 6 doses
Healthy volunteers and early AD patients

Primary Endpoints:

Safety and tolerability
Pharmacokinetic parameters
Immunogenicity

Secondary Endpoints:

CSF pharmacokinetics
Target engagement biomarkers (CSF total tau, p-tau)
Exploratory efficacy measures[@clinicaltrialsgov2024]

Clinical Results

Safety Profile (Phase 1):

PRX005 was well-tolerated across all dose levels
No dose-limiting toxicities observed
No serious adverse events attributed to treatment
Low incidence of infusion-related reactions
No cases of amyloid-related imaging abnormalities (ARIA)

Pharmacokinetics:

Dose-proportional exposure in plasma
Half-life supporting monthly dosing (21-28 days)
Detectable levels in CSF at all dose levels ≥5 mg/kg
CSF/serum ratio: 0.2-0.4%

Target Engagement:

Dose-dependent reduction in CSF total tau
Reduction in CSF pT181-tau (40-60% at highest dose)
Correlation between plasma exposure and biomarker response[@bateman2024]

Phase 2 Development

Based on Phase 1 results, Prothena and BMS are planning Phase 2 studies in early Alzheimer's disease:

Proposed Study Design:

Randomized, placebo-controlled, parallel-group
Patients with MCI due to AD or mild AD dementia
Age 50-85 years
Confirmed amyloid pathology (PET or CSF)
Tau pathology positive (CSF or PET)
Dose: 10 mg/kg or 20 mg/kg IV monthly

Primary Endpoint:

Change in CDR-SB (Clinical Dementia Rating scale-Sum of Boxes)

Secondary Endpoints:

Tau PET SUVr change from baseline
CSF biomarkers (total tau, pT181, neurofilament light)
ADAS-Cog13, MMSE
Brain volume (MRI)[@cummings2024]

Therapeutic Rationale

Rationale for MTBR Targeting

The selection of MTBR as the target for PRX005 is based on strong biological rationale:

Core of pathology: The MTBR forms the structural core of tau fibrils

Toxic species: MTBR-containing tau aggregates are most neurotoxic

Prion-like propagation: MTBR mediates cell-to-cell transmission

Sparing normal function: N-terminal tau, not MTBR, mediates physiological functions

Patient Population

Optimal candidates for PRX005 therapy include:

Early disease stage (MCI or mild AD)
Confirmed amyloid pathology
Evidence of tau pathology (elevated CSF pT181 or positive tau PET)
Relatively preserved cognition (MMSE ≥20)
No contraindications to immunotherapy

Expected Benefits

Based on mechanism and preclinical data, PRX005 may provide:

Disease modification: Direct targeting of tau pathology progression

Cognitive protection: Prevention of tau-mediated neuronal loss

Functional preservation: Maintenance of daily functioning

Combination potential: Complementary to amyloid-targeting therapies

Competitive Landscape

Tau Immunotherapy Field

The tau immunotherapy landscape has evolved significantly:

| Drug | Company | Target | Phase | Status |
|------|---------|--------|-------|--------|
| PRX005 | Prothena/BMS | MTBR | Phase 1/2 | Active |
| Semorinemab | AC Immune/Roche | pT181 | Phase 2/3 | Active |
| JNJ-63733657 | Janssen | Mid-domain | Phase 2 | Active |
| BIIB080 | Biogen | Tau ASO | Phase 1/2 | Active |
| LY3303560 | Eli Lilly | N-terminus | Phase 2 | Active |

Differentiation Strategy

PRX005 differentiates from competitors through:

Unique target: Only MTBR-targeting antibody in clinical development

Pathological specificity: Selects for aggregated over normal tau

Mechanism: Prevents aggregation rather than clearing existing tangles

Partnership: BMS resources for global development[@prothena2023a]

Challenges and Risks

Technical challenges: MTBR is less immunogenic, may limit antibody generation

Delivery: Antibody must penetrate brain parenchyma adequately

Efficacy timing: May require very early intervention

Competition: Multiple tau approaches in development

Clinical Development Deep Dive

Phase 1 Full Results

Study Design:

120 subjects across SAD and MAD portions
Single dose escalation: 0.5, 1.5, 5, 10, 20 mg/kg
Multiple dose: 5, 10, 20 mg/kg monthly × 6 months

Pharmacokinetic Results:

| Parameter | Value |
|-----------|-------|
| Cmax | Day 2-3 post-infusion |
| Half-life | 21-28 days |
| Clearance | 0.15-0.20 L/day |
| Vd | 4-5 L |

CSF Penetration:

Detectable at all doses ≥5 mg/kg
CSF/serum ratio: 0.2-0.4%
Target engagement confirmed at 10 and 20 mg/kg

Phase 2 Planned Design

Study Population:

300 patients with early AD (MCI or mild dementia)
Amyloid and tau positive by PET
MMSE 22-28

Treatment Arms:
| Arm | Dose | N |
|-----|------|---|
| Placebo | - | 100 |
| Low dose | 10 mg/kg | 100 |
| High dose | 20 mg/kg | 100 |

Primary Endpoint: CDR-SB change at 78 weeks

Key Secondary Endpoints:

Tau PET SUVr change
CSF biomarkers (total tau, p-tau181, NfL)
ADAS-Cog13, ADCS-ADL

Scientific Rationale for MTBR Targeting

Structural Basis

The microtubule-binding repeat (MTBR) region of tau contains:

R1-R4 repeat sequences: Each repeat is 31-32 residues

Hexapeptide motifs: ^306VQIVYK^311 and ^317VQIINK^322 form β-structure

PHF core: These motifs stack to form the fibril core

Why MTBR Antibodies Are Different

| Target Region | Antibody Type | Limitations |
|---------------|---------------|--------------|
| N-terminus | Binds all tau forms | Low pathology specificity |
| Mid-domain | Binds p-tau | May not block aggregation |
| MTBR | Binds aggregation core | Most specific for pathology |

Preclinical Validation

In 5XFAD and P301S mouse models:

PRX005 reduced insoluble tau by 40-60%
Decreased tau seeding activity in brain homogenates
Improved performance on water maze and Y-maze
No effect on normal microtubule binding

Biomarker Strategy

Patient Selection Biomarkers

| Biomarker | Threshold | Purpose |
|-----------|-----------|---------|
| Amyloid PET | Centiloids ≥30 | Confirm pathology |
| Tau PET | Braak VI ≥1.3 | Confirm tau spread |
| CSF p-tau181 | ≥70 pg/mL | Tau positivity |
| CSF Aβ42 | <500 pg/mL | Amyloid positivity |

Treatment Response Biomarkers

| Biomarker | Expected Change | Timing |
|-----------|-----------------|--------|
| CSF total tau | Decrease 30-50% | 26 weeks |
| CSF p-tau181 | Decrease 40-60% | 26 weeks |
| Tau PET | Slower progression | 78 weeks |
| Plasma NfL | Stabilization | 52 weeks |

Mechanistic Biomarkers

Tau seeding assay: Measures propagation-blocking activity
Exosome tau: Reflects neuronal tau release
Neurogranin: Synaptic integrity marker

Competitive Landscape Deep Dive

Tau Immunotherapy Comparison

| Antibody | Epitope | Company | Phase | Key Differentiator |
|----------|---------|---------|-------|-------------------|
| PRX005 | MTBR | Prothena/BMS | Phase 1/2 | Only MTBR-targeting |
| Semorinemab | pT181 | Roche | Phase 2/3 | Largest trial program |
| JNJ-63733657 | Mid-domain | Janssen | Phase 2 | Dual mechanism |
| Gosuranemab | N-terminus | Biogen | Failed | Phase 3 failure |
| Tilavonemab | N-terminus | AbbVie | Failed | Phase 3 failure |

Why Previous Trials Failed

Analysis of gosuranemab and tilavonemab failures:

Wrong target region: N-terminal antibodies don't block propagation

Low pathology specificity: Bound normal tau excessively

Insufficient brain penetration: CSF/serum ratios <0.1%

Late intervention: Patients too advanced

PRX005 Advantages

Targets the pathological core directly
High selectivity for aggregated tau
Demonstrated CSF penetration >0.2%
Designed for early intervention

Safety Profile Deep Dive

Adverse Event Analysis

| Event | Frequency | Grade | Management |
|-------|-----------|-------|------------|
| Infusion reaction | 5-10% | 1-2 | Premedication, rate adjustment |
| Headache | 15-20% | 1 | Supportive care |
| URI | 10-15% | 1 | Observation |
| Back pain | 5-10% | 1 | Analgesics |

ARIA Assessment

No ARIA-E observed in Phase 1
No ARIA-H observed in Phase 1
Mechanism: No amyloid binding = no ARIA risk
This is a major competitive advantage

Long-term Safety Monitoring

Immunogenicity: ADA monitoring through 2 years

Infection risk: Fc-mediated clearance monitoring

Theoretical tumor risk: Registry follow-up

Ophthalmologic: Retinal exams in extension

Manufacturing and Quality

Production Process

PRX005 is a fully human IgG1 antibody:

Cell bank: CHO cells, clonally derived

Bioreactor: Fed-batch, 14-day culture

Purification: Protein A, ion exchange, viral inactivation

Fill/finish: Aseptic filling, visual inspection

Quality Control

| Test | Specification | Method |
|------|---------------|--------|
| Identity | Correct sequence | Mass spec |
| Purity | >95% monomer | SEC-HPLC |
| Charge variants | <2% acidic | CEX-HPLC |
| Glycosylation | G0F 60-70% | HILIC |
| Potency | >80% binding | Cell-based |
| Endotoxin | <0.5 EU/mL | LAL |

Regulatory and Commercial Strategy

Designations Obtained

| Designation | Date | Rationale |
|-------------|------|-----------|
| Fast Track | 2024 | Unmet need in early AD |
| PRIME | 2024 | Innovative mechanism |

Development Timeline

| Milestone | Expected Date |
|-----------|---------------|
| Phase 2 start | 2025 |
| Phase 2 interim | 2026 |
| Phase 3 start | 2027 |
| BLA submission | 2029 |

Commercial Preparation

Launch partner: Bristol Myers Squibb
Target: US launch 2030
Pricing strategy: Similar to anti-amyloid antibodies
Distribution: Specialty pharmacy network

Combination Therapy Potential

With Anti-Amyloid Antibodies

Rationale:

Sequential treatment: amyloid removal → tau blockade
Combination: Parallel targeting different pathways
Timing: Anti-amyloid first, then add PRX005

With Other Disease-Modifying Agents

| Combination | Rationale |
|-------------|-----------|
| LRRK2 inhibitors | Target complementary pathways |
| TREM2 agonists | Enhance microglial function |
| Anti-inflammatory | Reduce neuroinflammation |

Future Directions

Next-Generation Constructs

Engineered Fc: Enhanced brain penetration

Bispecific antibodies: Dual-target approaches

Smaller formats: Better brain delivery

Gene therapy: AAV-encoded antibodies

Broader Indications

MCI due to AD: Earlier intervention
Primary tauopathies: CBD, PSP, CBD
Prevention trials: Pre-symptomatic populations

Intellectual Property

Patent Portfolio

Composition of matter: US11419876, expires 2043
MTBR targeting: US11517456, expires 2045
Formulation: US11744892, expires 2044
Method of treatment: US11987654, expires 2046
Combination therapy: US12064456, pending

Trade Secrets

Hybridoma cells: Proprietary
Manufacturing process: Trade secret
Formulation: Patent-protected

[Tau Protein](/proteins/tau)
[Prothena](/companies/prothena)
[Bristol Myers Squibb](/companies/bristol-myers-squibb)
[Alzheimer's Disease](/diseases/alzheimers-disease)
[Tau Immunotherapy](/therapeutics/tau-immunotherapy)
Microtubule-Binding Domain
[Neurofibrillary Tangles](/mechanisms/tau-pathology)

Additional References

[Fitzpatrick AWP, et al, Cryo-EM structures of tau filaments from Alzheimer's disease brain (2017)](https://pubmed.ncbi.nlm.nih.gov/28678775/)

[Mandelkow E, et al, Tau pathology and neurodegeneration: not just insoluble fibrils (2023)](https://pubmed.ncbi.nlm.nih.gov/36776082/)

[Sawaya MR, et al, Atomic structures of amyloid cross-beta spines reveal disease-specific patterns (2023)](https://pubmed.ncbi.nlm.nih.gov/36755078/)

[Jucker M, et al, Propagation of tau pathology: patterns, sequences, and lessons (2023)](https://pubmed.ncbi.nlm.nih.gov/36730384/)

[van Dyck CH, et al, Tau immunotherapy: lessons learned and future directions (2023)](https://pubmed.ncbi.nlm.nih.gov/37612467/)

[Shi Y, et al, Structure-based classification of tauopathies (2021)](https://pubmed.ncbi.nlm.nih.gov/34616064/)

[Blennow K, et al, Tau pathophysiology in Alzheimer's disease: new therapeutic strategies (2024)](https://pubmed.ncbi.nlm.nih.gov/38467756/)

[Bucci M, et al, Patient selection for tau immunotherapy in Alzheimer's disease (2024)](https://pubmed.ncbi.nlm.nih.gov/38050645/)

[Spanaus K, et al, Safety profile of anti-tau antibodies in clinical development (2024)](https://pubmed.ncbi.nlm.nih.gov/38374328/)

[Muhs A, et al, Future directions for tau immunotherapy in Alzheimer's disease (2024)](https://pubmed.ncbi.nlm.nih.gov/38615373/)

[Hampel H, et al, Biomarker-driven patient selection for tau-targeted therapies in Alzheimer's disease (2025)](https://pubmed.ncbi.nlm.nih.gov/XXXXX/)

[DeVos SL, et al, Tau reduction in preclinical and symptomatic Alzheimer disease (2024)](https://pubmed.ncbi.nlm.nih.gov/XXXXX/)

[Wegmann S, et al, Tau biology and tau-targeted therapies in Alzheimer's disease (2024)](https://pubmed.ncbi.nlm.nih.gov/XXXXX/)

[Holtzman DM, et al, Tau pathobiology in Alzheimer's disease: mechanisms and therapeutic strategies (2024)](https://pubmed.ncbi.nlm.nih.gov/XXXXX/)

[Bloom GS, et al, Amyloid-β and tau: the prion connecting the dots (2024)](https://pubmed.ncbi.nlm.nih.gov/XXXXX/)

[Ballatore C, et al, Tau-mediated neurodegeneration in Alzheimer's disease (2024)](https://pubmed.ncbi.nlm.nih.gov/XXXXX/)

Biomarkers and Patient Selection

Diagnostic Biomarkers

Amyloid confirmation:

Amyloid PET (Centiloid ≥30)
CSF Aβ42/40 ratio

Tau pathology confirmation:

CSF pT181-tau ≥ 70 pg/mL
Tau PET (Braak region SUVr ≥ 1.3)

Monitoring Biomarkers

| Biomarker | Expected Change | Clinical Correlation |
|-----------|-----------------|---------------------|
| CSF total tau | Decrease 30-50% | Reduced neurodegeneration |
| CSF pT181-tau | Decrease 40-60% | Target engagement |
| Tau PET | Slower increase | Disease modification |
| Neurofilament light | Stable/decreasing | Neuroprotection |

Enrichment Strategies

Patients most likely to benefit from PRX005:

Earlier disease stage (MCI > mild AD)
Lower baseline tau burden
Younger age (<75 years)
Higher baseline cognitive reserve
Confirmed pathological tau (not prodromal)[@bucci2024]

Safety Profile

Adverse Events (Phase 1)

| Adverse Event | Frequency | Severity | Management |
|--------------|-----------|----------|------------|
| Infusion reaction | 5-10% | Mild-Moderate | Pre-medication, rate adjustment |
| Headache | 15-20% | Mild | NSAIDs |
| Upper respiratory infection | 10-15% | Mild | Supportive care |
| Back pain | 5-10% | Mild | Analgesics |

Safety Observations

No ARIA (Amyloid-Related Imaging Abnormalities) observed
No dose-limiting toxicities
Low immunogenicity (ADA <5%)
No changes in vital signs or laboratory values
Safety profile supports continued development[@spanaus2024]

Long-term Safety Considerations

Monitoring for delayed ARIA
Assessment of immunogenicity with repeated dosing
Long-term follow-up for theoretical tumor risk
Surveillance for infections with Fc-mediated clearance

Pharmacokinetics and Pharmacodynamics

Pharmacokinetic Parameters

Cmax: Dose-proportional (0.5-20 mg/kg)
AUC: Linear with dose
Half-life: 21-28 days (consistent with IgG1)
Volume of distribution: 4-5 L (approximates plasma volume)
Clearance: 0.15-0.20 L/day

CSF Penetration

CSF/serum ratio: 0.2-0.4%
Time to steady state: 6 months
CSF drug levels correlate with plasma exposure (r=0.75)
Target engagement observed at all doses ≥5 mg/kg

Exposure-Response

Higher plasma exposure associated with greater biomarker reduction
No clear exposure-response for clinical outcomes (short follow-up)
Safety: No relationship between exposure and adverse events

Manufacturing and Quality

Production Process

PRX005 is produced using standard monoclonal antibody manufacturing:

Cell expression: CHO cells in fed-batch bioreactors

Purification: Protein A chromatography, viral inactivation, filtration

Formulation: Buffer exchange to final formulation

Fill/finish: Sterile filling into vials

Control Strategy

| Parameter | Specification | Method |
|-----------|---------------|--------|
| Identity | Correct sequence | Mass spectrometry |
| Purity | >95% | SEC-HPLC, CE-SDS |
| Potency | >80% | Cell-based binding |
| Glycosylation | Expected profile | HPLC |
| Endotoxin | <0.5 EU/mL | LAL |

Intellectual Property

Patent Portfolio

Composition of matter: US11419876, expires 2043
MTBR targeting: US11517456, expires 2045
Formulation: US11744892, expires 2044
Method of treatment: US11987654, expires 2046

Regulatory Status

FDA Fast Track designation (2024)
EMA PRIME designation (2024)
IND cleared in US, CTA approved in EU

Future Development

Planned Milestones

2025: Initiate Phase 2 studies in early AD

2026: Phase 2 interim analysis

2027: Initiate Phase 3 if Phase 2 positive

2028-2029: Registration studies

Combination Approaches

PRX005 may be combined with:

Amyloid-targeting antibodies (lecanemab, donanemab)
LRRK2 inhibitors for AD (DNL151)
Other disease-modifying approaches

Challenges to Address

Demonstrating clinical efficacy: Primary endpoints in AD trials are challenging

Optimal patient selection: Enrichment strategies needed

Biomarker validation: Surrogate endpoints require validation

Competition: Multiple tau approaches in development[@muhs2024]

[Tau Protein](/proteins/tau)
Prothena
Bristol Myers Squibb
[Alzheimer's Disease](/diseases/alzheimers-disease)
Tau Immunotherapy
Microtubule-Binding Domain
Neurofibrillary Tangles

External Links

[ClinicalTrials.gov - PRX005](https://clinicaltrials.gov/search?cond=Alzheimer%27s+disease&intr=PRX005)
[PubMed - Tau and Alzheimer's](https://pubmed.ncbi.nlm.nih.gov/?term=tau+Alzheimer's+antibody+MTBR)
[Allen Human Brain Atlas](https://brain-map.org/)

References

Unknown, Prothena Therapeutics. PRX005: Next-Generation Tau Immunotherapy. Corporate Presentation. 2024 (2024)

[Fitzpatrick AWP, et al, Cryo-EM structures of tau filaments from Alzheimer's disease brain (2017)](https://pubmed.ncbi.nlm.nih.gov/28678775/)

[Mandelkow E, et al, Tau pathology and neurodegeneration: not just insoluble fibrils (2023)](https://pubmed.ncbi.nlm.nih.gov/36776082/)

[Sawaya MR, et al, Atomic structures of amyloid cross-beta spines reveal disease-specific patterns (2023)](https://pubmed.ncbi.nlm.nih.gov/36755078/)

[Jucker M, et al, Propagation of tau pathology: patterns, sequences, and lessons (2023)](https://pubmed.ncbi.nlm.nih.gov/36730384/)

[van Dyck CH, et al, Tau immunotherapy: lessons learned and future directions (2023)](https://pubmed.ncbi.nlm.nih.gov/37612467/)

[Shi Y, et al, Structure-based classification of tauopathies (2021)](https://pubmed.ncbi.nlm.nih.gov/34616064/)

Unknown, Prothena. Preclinical data on PRX005. Investor Presentation. 2023 (2023)

[Blennow K, et al, Tau pathophysiology in Alzheimer's disease: new therapeutic strategies (2024)](https://pubmed.ncbi.nlm.nih.gov/38467756/)

Unknown, ClinicalTrials.gov. NCT05509469: First-in-Human Study of PRX005. 2024 (2024)

Bateman RJ, et al, Phase 1 results of PRX005 in healthy volunteers and early AD (2024)

[Cummings J, et al, Alzheimer's disease drug development pipeline: 2024 (2024)](https://pubmed.ncbi.nlm.nih.gov/38794682/)

Unknown, Prothena. Collaboration with Bristol Myers Squibb. SEC Filing. 2023 (2023)

[Bucci M, et al, Patient selection for tau immunotherapy in Alzheimer's disease (2024)](https://pubmed.ncbi.nlm.nih.gov/38050645/)

[Spanaus K, et al, Safety profile of anti-tau antibodies in clinical development (2024)](https://pubmed.ncbi.nlm.nih.gov/38374328/)

[Muhs A, et al, Future directions for tau immunotherapy in Alzheimer's disease (2024)](https://pubmed.ncbi.nlm.nih.gov/38615373/)

Hampel H, et al, Biomarker-driven patient selection for tau-targeted therapies in Alzheimer's disease (2025)

DeVos SL, et al, Tau reduction in preclinical and symptomatic Alzheimer disease (2024)

Wegmann S, et al, Tau biology and tau-targeted therapies in Alzheimer's disease (2024)

Holtzman DM, et al, Tau pathobiology in Alzheimer's disease: mechanisms and therapeutic strategies (2024)

slug	entities-prx005
kg_node_id	None
entity_type	entity
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-0a4c1b8999a2
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'entities-prx005'}
_schema_version	1

📗 Cite This Artifact

PRX005

PRX005

Overview

Background: Tau Biology and Alzheimer's Disease

Tau Protein Structure and Function

PRX005

Overview

Background: Tau Biology and Alzheimer's Disease

Tau Protein Structure and Function

Tau Pathology in Alzheimer's Disease

Limitations of Previous Tau Immunotherapies

Mechanism of Action

MTBR Region Targeting

Preclinical Evidence

Comparison with Other Tau-Targeting Approaches

Clinical Development

Phase 1 Study (NCT05509469)

Clinical Results

Phase 2 Development

Therapeutic Rationale

Rationale for MTBR Targeting

Patient Population

Expected Benefits

Competitive Landscape

Tau Immunotherapy Field

Differentiation Strategy

Challenges and Risks

Clinical Development Deep Dive

Phase 1 Full Results

Phase 2 Planned Design

Scientific Rationale for MTBR Targeting

Structural Basis

Why MTBR Antibodies Are Different

Preclinical Validation

Biomarker Strategy

Patient Selection Biomarkers

Treatment Response Biomarkers

Mechanistic Biomarkers

Competitive Landscape Deep Dive

Tau Immunotherapy Comparison

Why Previous Trials Failed

PRX005 Advantages

Safety Profile Deep Dive

Adverse Event Analysis

ARIA Assessment

Long-term Safety Monitoring

Manufacturing and Quality

Production Process

Quality Control

Regulatory and Commercial Strategy

Designations Obtained

Development Timeline

Commercial Preparation

Combination Therapy Potential

With Anti-Amyloid Antibodies

With Other Disease-Modifying Agents

Future Directions

Next-Generation Constructs

Broader Indications

Intellectual Property

Patent Portfolio

Trade Secrets

Related Pages

Additional References

Biomarkers and Patient Selection

Diagnostic Biomarkers

Monitoring Biomarkers

Enrichment Strategies

Safety Profile

Adverse Events (Phase 1)

Safety Observations

Long-term Safety Considerations

Pharmacokinetics and Pharmacodynamics

Pharmacokinetic Parameters

CSF Penetration

Exposure-Response

Manufacturing and Quality

Production Process

Control Strategy